Malignant Peritoneal and Retroperitoneal Neoplasm

Malignant Peritoneal and Retroperitoneal Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

631 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 163
Recruiting: 76
Ph III recruiting: 8
Growth YoY: −39.1%
Industry share: 15%
Top sponsor: National Cancer Institute (NCI)
Termination share: 31.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (92)

clinicaltrialsPublishedShowing 51–100 of 631 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06580314	Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer	recruiting	Phase 3	880	NRG OncologyOTHER	3	Aug 7, 2026	clinicaltrials
NCT03026062	Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	completed	Phase 2	100	M.D. Anderson Cancer CenterOTHER	1	Aug 5, 2026	clinicaltrials